Expression studies for breast, lung, prostate, gastric, and renal cancers as well as glioma, melanoma, and acute lymphoblastic leukemia support the heterogeneity of AGO-expression levels in cancer. This evidence concerns the gene FBXW7 and central nervous system cancer.